Stocks of Surmodics, Inc (NASDAQ:SRDX) traded higher last session on Wall Street, up 0.66% to $36.88.
SRDX stock price is now -5.54% away from the 50-day moving average and -2.81% away from the 200-day moving average. The market capitalization of the company currently stands at $527.17M.
With the price target maintained at $36, Needham recently Upgraded its rating from Hold to Buy for Surmodics, Inc (NASDAQ: SRDX). , while the Needham previously rated the stock as ‘Buy’ on July 23, 2020.
In other news, Arens Timothy J., Chief Financial Officer sold 7,009 shares of the company’s stock on Nov 26 ’24. The stock was sold for $276,453 at an average price of $39.44. Upon completion of the transaction, the Chief Financial Officer now directly owns 70,350 shares in the company, valued at $2.59 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 26 ’24, Officer TIMOTHY ARENS bought 7,009 shares of the business’s stock. A total of $276,453 was incurred on buying the stock at an average price of $39.44. A total of 4.10% of the company’s stock is owned by insiders.
During the past 12 months, Surmodics, Inc has had a low of $25.17 and a high of $42.44. As of last week, the company has a debt-to-equity ratio of 0.28, a current ratio of 3.96, and a quick ratio of 3.22. The fifty day moving average price for SRDX is $39.0448 and a two-hundred day moving average price translates $37.94625 for the stock.
The latest earnings results from Surmodics, Inc (NASDAQ: SRDX) was released for 2024-09-30. The net profit margin was -9.15% and return on equity was -9.67% for SRDX. The company reported revenue of $33.23 million for the quarter, compared to $27.97 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 18.8 percent. For the current quarter, analysts expect SRDX to generate $33.37M in revenue.